GLP-1 medications, like semaglutide and tirzepatide, are best known for two things: significant weight loss and improved blood sugar control.
In addition, a growing body of research is pointing to another effect: reductions in inflammatory markers like C-reactive protein (CRP).
So what does this actually mean? Are GLP-1 medications directly reducing inflammation, or is this a byproduct of weight loss and improved metabolic health? And if inflammation does improve, does that change how you should be eating while taking these medications?
In this article, we’ll look at what the research shows about GLP-1 medications and inflammation, why this effect occurs, and how it compares with improvements in inflammatory markers from diet and lifestyle alone. A reduction in CRP can reflect improved systemic inflammation. Still, it doesn’t replace the need to adequately nourish your body or mean medication is the only way to improve inflammatory health.
These medications can significantly reduce appetite and food intake, so adequate nutrition becomes an important factor during treatment. We’ll cover this in detail toward the end.
What Is Inflammation?
Inflammation is a normal and healthy response of your immune system to an infection, injury, or other threat.
Acute inflammation helps your body defend itself, remove damaged cells, and begin healing, typically within hours to days.
In chronic inflammation, the immune system stays active for months or years instead of returning to baseline. It can continue after the original trigger has passed or result from an underlying medical condition.
Over time, this ongoing inflammatory response can damage healthy tissues and interfere with normal body function.
Chronic systemic inflammation is associated with several chronic diseases, including cardiovascular disease and type 2 diabetes.
If you want a deeper explanation of what chronic inflammation is, what causes it, and what can help, read my full guide to chronic inflammation.
C-reactive protein (CRP) is a protein produced by the liver that rises in response to inflammation. High-sensitivity CRP (hsCRP) measures the same protein but uses a more sensitive test to detect the lower levels of inflammation relevant to cardiovascular risk.
| hsCRP level | Traditional cardiovascular-risk interpretation |
| <1 mg/L | Lower risk |
| 1–3 mg/L | Intermediate/average risk |
| >3 mg/L | Higher risk |
Note: An hsCRP level of ≥2 mg/L is also considered a cardiovascular risk-enhancing factor.
Values >10 mg/L may reflect an acute infection, injury, or another inflammatory process and should be interpreted in that clinical context rather than simply as “very high cardiovascular risk.”
Remember that CRP and hsCRP are nonspecific markers of systemic inflammation. The reductions seen in GLP-1 studies do not mean these medications are established treatments for autoimmune diseases such as rheumatoid arthritis.
However, GLP-1s may still be prescribed for separate indications such as obesity or type 2 diabetes in someone who also has an autoimmune condition, and researchers are actively studying whether GLP-1 medications have additional effects on autoimmune inflammatory pathways.
What Are GLP-1 Medications?
In basic terms, GLP-1 medications mimic the effects of naturally occurring gut hormones that help regulate appetite, satiety (fullness), blood sugar, and how quickly food leaves the stomach. Together, these effects can reduce appetite and support significant weight loss.
Interestingly, part of the story behind this medication class traces back to the Gila monster, a large venomous lizard (and a favorite of my boys) that can go months without eating. Researchers discovered exendin-4, a peptide in its salivary secretions that activates the GLP-1 receptor and remains active in the body far longer than natural GLP-1. This discovery eventually led to exenatide, one of the first GLP-1 medications.
GLP-1 stands for glucagon-like peptide-1. GLP-1 receptor agonists (GLP-1 RAs) activate the GLP-1 receptor. The term “GLP-1 medications” is used more broadly to include dual GIP/GLP-1 receptor agonists such as tirzepatide, which activate both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors.
Common GLP-1 medications include:
- Ozempic: semaglutide, primarily used for type 2 diabetes
- Wegovy: semaglutide, used for chronic weight management
Common dual GIP/GLP-1 medications include:
- Mounjaro: tirzepatide, used for type 2 diabetes
- Zepbound: tirzepatide, used for chronic weight management
These medications also improve glucose control by helping the body release insulin when blood sugar is elevated and reducing glucagon, a hormone made by your pancreas that raises blood sugar. Semaglutide and tirzepatide are often given as once-weekly injections. Oral GLP-1 options are also available, including oral semaglutide (Wegovy tablets) and orforglipron (Foundayo), a newer once-daily GLP-1 receptor agonist.
These effects on appetite, body weight, and metabolic health may help explain why researchers are also seeing changes in inflammation markers.
Do GLP-1 Medications Reduce Inflammation?
The short answer is yes; current research shows GLP-1 medications can reduce systemic inflammation. Studies consistently show meaningful reductions in CRP and hsCRP among people taking GLP-1-based medications. Researchers are still trying to figure out exactly why these improvements occur.
Semaglutide and CRP
In a 2022 analysis of three large STEP trials including 3,782 adults with overweight or obesity, participants taking semaglutide 2.4 mg had significantly greater reductions in CRP than those taking the placebo.
After 68 weeks, CRP was reduced by about 39-48% more with semaglutide than placebo, depending on the trial. The improvement was seen regardless of participants’ starting weight, BMI, blood sugar status, or CRP level.
CRP decreased alongside weight loss and improvements in waist circumference, glucose, insulin, and insulin resistance, making it difficult to determine how much of the anti-inflammatory effect came directly from semaglutide versus improvements in weight and metabolic health.
Tirzepatide and hsCRP
In a 2026 analysis of 392 participants from SURMOUNT-1, tirzepatide reduced hsCRP by about 51–65% from baseline, or roughly 37–55% more than placebo, depending on dose. Greater weight and waist reductions were linked with larger hsCRP decreases, but researchers could not determine how much was due to weight loss versus other effects of tirzepatide.
Oral GLP-1 Medications and Inflammation
Oral GLP-1 medications have shown similar improvements in inflammatory markers.
In three randomized PIONEER trials of adults with type 2 diabetes, oral semaglutide lowered hsCRP by approximately 18–37% from baseline, depending on the trial and dose. Researchers found that improvements in body weight and blood sugar explained part of the hsCRP reduction, suggesting that better metabolic health contributes to the anti-inflammatory effect.
A newer oral GLP-1 medication, orforglipron, has also shown promising effects on inflammation. In the 72-week ATTAIN-1 trial of 3,127 adults with overweight or obesity without diabetes, the highest dose of orforglipron reduced hsCRP by 47.7%. Participants taking that dose also lost an average of about 12.4% of their body weight, again making it difficult to separate changes in inflammation from the effects of substantial weight loss and improved metabolic health.
Elevated CRP is associated with cardiovascular risk, but lowering CRP alone does not prove that reduced inflammation drives better cardiovascular outcomes.
These large, comprehensive studies suggest that GLP-1 medications can improve systemic inflammatory markers. Still, they also raise a key question: how much of that improvement comes from the medication itself, and how much from weight loss and improved metabolic health?
How GLP-1 Medications Compare with Diet and Exercise
Here’s how those inflammation reductions stack up against non-medication approaches:
| Approach | CRP/hsCRP change reported | Study size | Age | Population | Study |
| Injectable GLP-1–based medication | Semaglutide: 39–48% ↓CRP vs. placebo Tirzepatide: approximately 37–55% ↓ hsCRP vs placebo | Semaglutide STEP 1–3: 3,782 total; SURMOUNT-1: 392 (from 2,539 total) | ~mid-40s to mid-50s | Adults with overweight/obesity, with and without T2D depending on the trial | Verma 2022; SURMOUNT-1 2026 |
| Oral GLP-1 medication | Oral semaglutide: ~18–37% ↓ hsCRP from baseline Oral orforglipron: 47.7% ↓ hsCRP at highest dose in ATTAIN-1 | PIONEER trials: 703 / 822 / 324; ATTAIN-1: 3,127 | ~55–70 y in PIONEER; middle aged adults in ATTAIN-1 | Adults with T2D or overweight/obesity, depending on trial | Mosenzon 2022; ATTAIN-1 |
| Lifestyle-induced weight loss | 24.7% ↓ hsCRP at 6 months with ~6.7% weight loss | 710 | ~51 y | Adults with overweight/obesity | Nicklas 2013 |
| Mediterranean-style diet | ≥16% ↓ in several inflammatory markers, including hsCRP, over long-term follow-up | 165 | ~66 y | Adults at high cardiovascular risk | Casas 2016 |
| Aerobic exercise | Individual RCT: ~10% ↓ at 16 weeks; ~51% ↓ at 32 week follow-up | 45 total | ≥65 y | Previously sedentary older adults | Martins 2010 |
| Resistance training | Individual RCT: ~11% ↓ at 16 weeks; ~39% ↓ at 32 week follow-up | 45 total | ≥65 y | Previously sedentary older adults | Martins 2010 |
Important: These studies differed in population, starting CRP levels, intervention length, medication dose, and amount of weight loss. The results show the magnitude of changes reported in research and should not be interpreted as head-to-head comparisons between medications, diet, and exercise.
A larger meta-analysis of 83 controlled trials involving 3,769 adults also found that exercise significantly reduced CRP overall, with greater reductions when BMI decreased, but significant improvements even without weight loss.
These studies show that GLP-1 medications, weight loss, eating patterns, and exercise can all influence inflammatory markers such as CRP. Next, we will jump into why GLP-1 medications lower inflammation and how the effect may come from weight loss and improved metabolic health rather than the medication alone.
Why Might GLP-1 Medications Lower Inflammation?
1. Weight Loss Reduces Inflammatory Signaling
Weight loss itself lowers CRP, regardless of how you lose weight. In a 2007 systematic review of lifestyle and surgical weight-loss studies, CRP declined by an average of 0.13 mg/L for every kilogram of weight lost. In general, greater weight loss was associated with greater reductions in CRP.
One likely mechanism is that excess fat tissue produces inflammatory cytokines that stimulate CRP production in the liver.
Both the STEP and SURMOUNT-1 analyses found that larger reductions in body weight and waist circumference were associated with greater improvements in CRP or hsCRP, suggesting that weight loss explains an important part of the anti-inflammatory effect.
2. Better Blood Sugar and Metabolic Health
Type 2 diabetes and insulin resistance are closely linked with chronic low-grade inflammation.
In an analysis of SUSTAIN and PIONEER trials involving adults with type 2 diabetes, semaglutide lowered hsCRP and improved blood sugar control and body weight. Researchers estimated that changes in A1c, a measure of average blood sugar over the past 2–3 months, and body weight together explained about 21–62% of the reduction in hsCRP.
Better glucose control and overall metabolic health are another important reason inflammation improves with GLP-1 treatment.
3. Possible Direct Anti-Inflammatory Effects
GLP-1 medications may also have direct anti-inflammatory effects beyond weight loss and improved blood sugar, although this is emerging research. GLP-1, the hormone naturally produced in the body, has a wide range of regulatory and protective effects throughout the body.
Experimental research suggests that activating GLP-1 receptors (such as with medication) may influence immune cells and inflammatory signaling pathways, including NF-κB, and reduce inflammatory cytokines such as IL-6 and TNF-α.
However, much of this evidence comes from animal and laboratory studies using GLP-1 or older GLP-1 medications. Human studies still struggle to separate a direct medication effect from the substantial changes in weight and metabolic health that occur during treatment.
4. What Researchers Are Still Learning
Researchers are still learning how GLP-1 medications affect inflammation and other systems throughout the body. The first GLP-1 medication was approved for type 2 diabetes in 2005, and the first was approved for chronic weight management in 2014.
We don’t have decades of human data on continuous treatment. This matters because obesity is a chronic condition, and GLP-1 medications may need to be taken long term to maintain their beneficial effects. Researchers are still studying what continuous GLP-1 and GIP/GLP-1 receptor activation may mean over decades of use.
This doesn’t mean long-term problems will emerge, but it does mean we can’t answer every question about lifelong treatment. In the meantime, more than 50 years of research supports the benefits of balanced eating patterns, regular physical activity, and other healthy lifestyle habits for metabolic and inflammatory health.
Why Nutrition Still Matters While Taking a GLP-1
The saying “Every solution has its own set of problems” holds true: GLP-1s can help with meaningful weight loss, improved glycemic control, and reduced inflammation, but their effects on appetite and food intake can also create important nutritional challenges.
Appetite Suppression Can Make Nutrition Adequacy Harder
Research quantifies that GLP-1 users experience significant appetite loss and reduced energy intake, with estimates ranging from 16 to 39%.
While effective for supporting weight loss, emerging research suggests that nutrient inadequacies may be more common during GLP-1 treatment. When you eat substantially less food, it can be harder to consume enough protein, fiber, vitamins, and minerals, especially if the foods you do eat are not nutrient-dense.
In one 2025 study of 69 adults using GLP-1 medications, average intake fell well below reference levels for several nutrients. Participants consumed about half the recommended fiber and potassium, two-thirds of the reference amount for calcium and iron, and only about one-fifth of the reference amount for vitamin D.
A much larger observational study of 461,382 GLP-1 users without a previously documented nutritional deficiency found that 12.7% received a nutritional-deficiency or related diagnosis within six months and 22.4% within one year.
Vitamin D deficiency was the most commonly recorded diagnosis. The study relied on medical diagnosis codes rather than measuring nutrient intake or blood levels before and after treatment. So, it can’t tell us whether GLP-1 therapy caused these deficiencies or how much individual nutrient levels changed.
People with very low appetite, significant GI side effects, rapid weight loss, older adults, or those starting with lower muscle mass will likely need extra attention to protein, fluids, and overall nutrient intake.
Protein Helps Protect Lean Muscle
Weight loss itself, regardless of the cause, includes some loss of lean tissue, particularly when weight loss is rapid. Earlier in my career, I worked in the ICU, where early and adequate nutrition was a priority for patients of all body sizes to support healing and preserve muscle mass.
The same principle matters during intentional weight loss: losing weight and adequately nourishing the body are best achieved together.
Across 20 randomized controlled trials, lean mass accounted for about 35.2% of total weight lost with semaglutide, 25.4% with tirzepatide, 26.8% with liraglutide, and 26.2% with lifestyle interventions.
Resistance training and adequate protein intake are two key tactics for preserving muscle during weight loss. In the same analysis, lifestyle interventions that included resistance training had a lower proportion of weight loss coming from lean mass (about 17.5%). A recent review also recommends prioritizing adequate protein, resistance exercise, nutritional analysis, and body-composition monitoring during GLP-1 treatment.
Fiber Supports Gut and Metabolic Health
Fiber becomes a key nutrient during GLP-1 treatment, especially because constipation is a common side effect and fiber intake often decreases as overall food intake drops. Dietary fiber supports bowel regularity, blood sugar regulation, cholesterol levels, and the gut microbiome.
Fiber feeds healthy gut bacteria, which produce short-chain fatty acids that support the gut lining, help regulate inflammation, and can stimulate the body’s natural GLP-1 production.
Reaching fiber recommendations quickly isn’t always better. GLP-1 medications slow digestion and can cause GI symptoms, so increasing fiber gradually and drinking enough fluids is more realistic and improves tolerance.
Anti-Inflammatory Foods Provide What Medication Can’t
GLP-1 medication can help reduce food noise, support weight loss, and improve blood sugar control, all of which may help lower chronic systemic inflammation and improve cardiometabolic health.
But medication is only one tool. Anti-inflammatory foods nourish the body with fiber, protein, vitamins and minerals, healthy fats, and phytonutrients that medication cannot provide. When appetite is lower and you’re eating less overall, food quality becomes even more important. Every bite counts.
Foods to include more often:
- Vegetables (broccoli, leafy greens, tomatoes, carrots, peas)
- Fruits (berries, apples, citrus, bananas, grapes)
- Whole grains (oats, quinoa, brown rice, whole-grain breads, cereals, and pastas)
- Nuts and seeds (almonds, peanuts, chia seeds, ground flax seeds, hemp seeds)
- Lean proteins (poultry, fish, legumes, eggs, yogurt, kefir)
- Healthy fats (olive oil, avocado oil, avocados)
- Ginger and peppermint tea (anti-inflammatory and helps with GI side effects)
Need help putting these foods into practice? Start with my anti-inflammatory food list or use my 7-day anti-inflammatory meal plan for a full week of meal ideas.
When You Eat Less, Food Quality and Healthy Habits Matter More
Energy intake may decline by roughly 16–39% during GLP-1 treatment. So each meal and snack has to do more nutritional work. Regular meals (even if smaller) can make it easier to consistently meet protein, fluid, fiber, vitamin, and mineral needs.
A similar shift can happen in midlife and beyond: calorie needs may gradually decrease while needs for protein, vitamins, minerals, fiber, and other nutrients remain. In both situations, there is less room for foods that provide calories without much nutritional value.
A 2025 joint advisory from several nutrition and obesity organizations recommends pairing GLP-1 treatment with intentional nutrition and other healthy lifestyle habits. Priorities include:
- Small, nutrient-dense meals and snacks
- A source of protein each time you eat
- Fiber and adequate fluids
- Resistance training and regular movement
- Adequate sleep and stress management
GLP-1 medications can be a valuable tool for some people, but they work best alongside a nourishing eating pattern and other healthy lifestyle habits, not instead of them.
Important Considerations
Like all medications, GLP-1 drugs can cause side effects and are not appropriate for everyone.
The most common are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and delayed stomach emptying. In some people, ongoing vomiting or diarrhea can contribute to dehydration. Less common, but more serious concerns include gallbladder disease and pancreatitis.
Semaglutide and tirzepatide carry a boxed warning related to thyroid C-cell tumors observed in rodents. It is not known whether these medications cause medullary thyroid cancer in humans, and human studies have not clearly demonstrated the same risk seen in animal studies. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
Because benefits, risks, nutrition status, other medications, and health history vary, a healthcare provider should individualize GLP-1 treatment.
Frequently Asked Questions
Do GLP-1 medications reduce inflammation?
Yes. Current research shows that GLP-1 medications can reduce markers of systemic inflammation, including CRP and hsCRP. Researchers are still determining exactly how much of this effect comes from weight loss, improved metabolic health, and possible direct anti-inflammatory actions.
Is the decrease in inflammation just from weight loss?
Probably not entirely. Weight loss accounts for some of the reduced inflammation, since CRP also decreases with lifestyle- and surgery-induced weight loss. However, improved blood glucose control and other metabolic changes may also contribute, and researchers are still studying whether GLP-1 medications have direct anti-inflammatory effects.
Do I still need an anti-inflammatory diet while taking a GLP-1?
Appetite and food intake can decrease by 16-39% during GLP-1 treatment, making it harder to meet protein, fiber, vitamin, mineral, and fluid needs.
Anti-inflammatory foods provide nutrients medication cannot, including fiber, protein, vitamins and minerals, healthy fats, and phytonutrients. When appetite is lower and you’re eating less overall, food quality becomes even more important. Every bite counts.
Key Takeaways
- GLP-1-based medications can substantially lower inflammatory markers such as CRP and hsCRP.
- Weight loss and improved metabolic health may explain much of that reduction.
- Researchers are still studying possible direct anti-inflammatory effects.
- GLP-1 medications are relatively new, and the effects of decades of continuous use are not yet known.
- More than 50 years of research support the benefits of healthy eating patterns, physical activity, and other lifestyle habits for metabolic health and inflammatory markers.
- Because GLP-1 medications decrease appetite and food intake, adequate protein, micronutrients, fiber, fluids, and overall diet quality may become more important.
Let’s get UNstuck and stay UNstuck!